Company intelligence / Profile preview

ImmuneID

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

No clinical trial results have been publicly disclosed; programs are in preclinical discovery, with strong proof-of-concept in antibody-based profiling for viral triggers in post-acute sequelae of SARS-CoV-2 (long-COVID) and other indications.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodySmall moleculeBiologicRNA therapy
Industry: Biotech

Partnerships

ARCH Venture Partners (strategic investor and board representation)Longwood Fund (founder and investor)Alta Partners, Alexandria Venture Investments, Redwood Capital Investments, Section 32, Tekla Capital Management, In-Q-Tel, Pitango HealthTech, Xfund (venture investors, strategic collaboration inferred)

Beyond the preview

Go deeper on ImmuneID.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuneID.

Explore the full profile